Arrowhead Pharmaceuticals (NASDAQ:ARWR) Hits New 12-Month Low - What's Next?

Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Get Free Report) hit a new 52-week low on Monday . The stock traded as low as $9.57 and last traded at $9.63, with a volume of 217226 shares trading hands. The stock had previously closed at $10.68.

Wall Street Analysts Forecast Growth

ARWR has been the subject of several analyst reports. Royal Bank of Canada restated an "outperform" rating and set a $42.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, February 11th. Chardan Capital reaffirmed a "buy" rating and issued a $60.00 target price on shares of Arrowhead Pharmaceuticals in a report on Tuesday, February 11th. HC Wainwright reissued a "buy" rating and set a $80.00 price target on shares of Arrowhead Pharmaceuticals in a report on Wednesday, February 12th. StockNews.com raised Arrowhead Pharmaceuticals to a "sell" rating in a research note on Friday, December 20th. Finally, B. Riley restated a "buy" rating and issued a $38.00 price target (down from $51.00) on shares of Arrowhead Pharmaceuticals in a research note on Friday, February 14th. One research analyst has rated the stock with a sell rating, four have given a hold rating and six have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus price target of $41.44.

Remove Ads

Arrowhead Pharmaceuticals Stock Performance

The firm has a market capitalization of $1.62 billion, a price-to-earnings ratio of -2.28 and a beta of 0.99. The company has a debt-to-equity ratio of 7.27, a quick ratio of 6.09 and a current ratio of 6.09. The stock's fifty day moving average is $16.07 and its two-hundred day moving average is $18.86.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last issued its quarterly earnings results on Monday, February 10th. The biotechnology company reported ($1.39) EPS for the quarter, missing the consensus estimate of ($0.42) by ($0.97). Analysts forecast that Arrowhead Pharmaceuticals, Inc. will post -2.42 earnings per share for the current year.

Insider Buying and Selling

In other Arrowhead Pharmaceuticals news, CEO Christopher Richard Anzalone sold 51,425 shares of the business's stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $15.07, for a total transaction of $774,974.75. Following the completion of the transaction, the chief executive officer now directly owns 4,062,377 shares of the company's stock, valued at $61,220,021.39. The trade was a 1.25 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders sold a total of 276,839 shares of company stock worth $4,054,176 in the last three months. 4.30% of the stock is owned by insiders.

Institutional Trading of Arrowhead Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the business. Avoro Capital Advisors LLC lifted its holdings in Arrowhead Pharmaceuticals by 25.0% in the fourth quarter. Avoro Capital Advisors LLC now owns 11,111,111 shares of the biotechnology company's stock worth $208,889,000 after purchasing an additional 2,222,223 shares during the period. Norges Bank bought a new stake in Arrowhead Pharmaceuticals in the fourth quarter worth about $38,622,000. Farallon Capital Management LLC acquired a new position in shares of Arrowhead Pharmaceuticals in the 4th quarter worth approximately $11,821,000. Two Sigma Investments LP raised its holdings in shares of Arrowhead Pharmaceuticals by 281.3% in the 4th quarter. Two Sigma Investments LP now owns 794,373 shares of the biotechnology company's stock worth $14,934,000 after purchasing an additional 586,062 shares in the last quarter. Finally, State Street Corp lifted its stake in Arrowhead Pharmaceuticals by 8.8% during the third quarter. State Street Corp now owns 6,354,331 shares of the biotechnology company's stock valued at $123,083,000 after purchasing an additional 516,569 shares during the last quarter. Institutional investors own 62.61% of the company's stock.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.